Search results
Found 7186 matches for
Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.
Transforming delivery and activity of antisense oligonucleotides (ASOs) outside of the liver with high throughput in vivo ligand screens
This project is part of the Therapeutic Genomics Centre, a multidisciplinary programme of innovative approaches to treating rare genetic disorders and providing an enhanced training experience for DPhil applicants.
Developing a Precision RNA Editing Platform for Therapeutic Applications
This project is part of the Therapeutic Genomics Centre, a multidisciplinary programme of innovative approaches to treating rare genetic disorders and providing an enhanced training experience for DPhil applicants.
Pioneering genomics approaches to develop targeted antisense oligonucleotides for treatment of patients with rare neurological disorders
This project is part of the Therapeutic Genomics Centre, a multidisciplinary programme of innovative approaches to treating rare genetic disorders and providing an enhanced training experience for DPhil applicants.
Development of antisense oligonucleotide and base editing therapeutics for neurodevelopmental haploinsufficiency disorders
This project is part of the Therapeutic Genomics Centre, a multidisciplinary programme of innovative approaches to treating rare genetic disorders and providing an enhanced training experience for DPhil applicants.
Predicting the therapeutic potential of all single gene disorders
This project is part of the Therapeutic Genomics Centre, a multidisciplinary programme of innovative approaches to treating rare genetic disorders and providing an enhanced training experience for DPhil applicants.
Addressing the health economic challenges of evaluating the full costs and effects of genome-targeted therapies
This project is part of the Therapeutic Genomics Centre, a multidisciplinary programme of innovative approaches to treating rare genetic disorders and providing an enhanced training experience for DPhil applicants.
Targeting Enhancers to Treat Neurological Diseases
This project is part of the Therapeutic Genomics Centre, a multidisciplinary programme of innovative approaches to treating rare genetic disorders and providing an enhanced training experience for DPhil applicants.
In vivo reprogramming of Extracellular Vesicles for Targeted Drug Delivery of genome editors to the Central Nervous System
This project is part of the Therapeutic Genomics Centre, a multidisciplinary programme of innovative approaches to treating rare genetic disorders and providing an enhanced training experience for DPhil applicants.
Directed Evolution of Targeting Strategies for Precise Delivery of Genome Editors to Hematopoietic Stem Cells Using Extracellular Vesicles and Lipid Nanoparticles
This project is part of the Therapeutic Genomics Centre, a multidisciplinary programme of innovative approaches to treating rare genetic disorders and providing an enhanced training experience for DPhil applicants.
Peptide-mediated delivery of CRISPR-Cas genome editors in the eye
This project is part of the Therapeutic Genomics Centre, a multidisciplinary programme of innovative approaches to treating rare genetic disorders and providing an enhanced training experience for DPhil applicants.
Hear from our students
What is it like to undertake a DPhil at the Department of Paediatrics? We asked some of the students here to share their interests, their projects and why they picked this department at the University of Oxford, over all others.